editor
natur
histori
sever
liken
cytokin
releas
syndrom
cr
lead
ask
whether
counter
excess
cytokin
releas
would
therapeut
gener
moor
june
time
anecdot
report
indic
confus
agit
delirium
idiosyncrat
difficult
treat
despit
import
continu
address
delirium
neuropsychiatr
symptom
patient
lahu
et
al
experi
cr
come
experi
care
outcom
cart
immun
therapi
cancer
constel
fact
might
suggest
lesson
learn
cart
neurotox
appli
care
patient
howev
applic
done
caution
regard
neuropsychiatr
aspect
firstli
appropri
degre
caution
need
pathophysiolog
cart
neurotox
remain
unclear
present
time
unclear
whether
neurotox
symptom
occur
direct
effect
car
tcell
central
nervou
system
term
immun
effector
cellassoci
neurotox
syndrom
ican
systemat
cytokin
releas
syndrom
cr
shalabi
et
al
exampl
multipl
studi
support
find
cart
patient
develop
earli
cr
like
develop
neurotox
like
develop
sever
neurotox
rubin
et
al
gauthier
turtl
howev
specif
role
cytokin
cart
neurotox
precis
understood
present
time
addit
evid
applic
therapi
cr
overal
medic
approach
may
problemat
interest
care
includ
blockad
cytokin
human
inflammatori
respons
possibl
tocilizumab
receptor
antagonist
approv
us
food
drug
administr
fda
treatment
car
cellinduc
cr
moor
june
howev
question
whether
tocilizumab
actual
penetr
bloodbrain
barrier
complic
indic
use
tocilizumab
tend
worsen
depress
anxieti
pain
sleep
given
adult
patient
receiv
cart
knight
et
al
growth
interest
immunolog
aspect
psychiatr
ill
therapeut
welcom
within
psychiatri
context
import
worker
around
nation
consid
similar
cart
cr
inde
everi
reason
prepar
shortterm
longterm
neuropsychiatr
effect
novel
coronaviru
one
forget
acut
chronic
effect
enceph
lethargica
aros
influenza
pandem
mccall
et
al
howev
clearli
understand
actual
interact
inflammatori
molecul
brain
cart
crsinduc
condit
continu
studi
institut
import
pursu
immunebas
explan
pathophysiolog
therapi
caution
util
widest
rang
medic
literatur
hannahlis
schofield
phd
